Elliot Epner is an Oncology physician affiliated with Pennsylvania State University. OpenAlex indexes 93 publications with 4,822 citations (h-index 33); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
500 University Dr
Hershey, PA 170332360
Telephone
800-233-4082Provider last certified this registry record 24 Jun 2024.
Clinical trials
- S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma
Sponsor: SWOG Cancer Research Network
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
48 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20251 payment
- Exelixis Inc.Program year20251 payment
- Eisai Inc.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
63.3%Aromatase Inhibitor63.3%Anastrozole100%Part D<11 patientsNervous system
36.7%Nonergot Dopamine Agonist36.7%Neupro100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Mantle cell lymphoma management trends and novel agents: where are we going?
Therapeutic Advances in Hematology
2022 - Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia
Science Translational Medicine
2015
Similar KOLs
Other experts from the same institution or the same specialty.
Ramin Zand, MD, MPH
Pennsylvania State University
Allan Lipton, MD
Pennsylvania State University
Steven Ettinger, MD
Pennsylvania State University
Gerald Naccarelli, MD
Pennsylvania State University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”